CardioSource WorldNews | Page 50

1 # PRESCRIBED NOAC IN THE US*1 † 2-13 BEYOND EXTTENSIVE RANDOMIZED CLINICAL TRIALS, PUBLISHED SAFETY OUTCOMES FROM OBSERVATIONAL STUDIES OF REAL-WORLD PATIENTS†2-13 SIX INDICATIONS STRONG To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled For the treatment of deep vein thrombosis (DVT) For the treatment of pulmonary embolism (PE) For the reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE For the prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery For the prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery NOAC = non-vitamin K antagonist oral anticoagulant. *Among Factor Xa inhibitors and direct thrombin inhibitors. † Based on the following registries, claims databases, and studies: Optum Labs=16,253; IMS Health LifeLink=1,649; Truven Health=5,563; Danish registry=1,303; XAMOS=8,778; Symphony=3,654; ORTHO-TEP=1,043; Japanese registry=1,035; Dresden NOAC=1,776; XALIA=2,505; DOD database=27,467; XANTUS=6,784. Please see Important Safety Information on preceding pages. Please see accompanying Brief Summary of full Prescribing Information, including Boxed WARNINGS, on preceding pages, or visit www.XareltoHCP.com/PI.